Penumbra (P2NB34) Stock Overview
Designs, develops, manufactures, and markets medical devices in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
P2NB34 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Penumbra, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.81 |
| 52 Week High | US$58.09 |
| 52 Week Low | US$42.15 |
| Beta | 0.69 |
| 1 Month Change | 7.84% |
| 3 Month Change | 7.99% |
| 1 Year Change | n/a |
| 3 Year Change | 40.54% |
| 5 Year Change | n/a |
| Change since IPO | 21.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| P2NB34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | 0% | -0.07% | -1.6% |
| 1Y | n/a | -0.2% | 9.7% |
Return vs Industry: Insufficient data to determine how P2NB34 performed against the BR Medical Equipment industry.
Return vs Market: Insufficient data to determine how P2NB34 performed against the BR Market.
Price Volatility
| P2NB34 volatility | |
|---|---|
| P2NB34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.1% |
Stable Share Price: P2NB34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine P2NB34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 4,500 | Adam Elsesser | www.penumbrainc.com |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, and aspiration pump under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as detachable coils to treat patients with a wide range of neurovascular lesions under the Penumbra SMART COIL and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
Penumbra, Inc. Fundamentals Summary
| P2NB34 fundamental statistics | |
|---|---|
| Market cap | R$61.05b |
| Earnings (TTM) | R$886.34m |
| Revenue (TTM) | R$7.21b |
Is P2NB34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P2NB34 income statement (TTM) | |
|---|---|
| Revenue | US$1.33b |
| Cost of Revenue | US$442.81m |
| Gross Profit | US$890.99m |
| Other Expenses | US$726.97m |
| Earnings | US$164.03m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.19 |
| Gross Margin | 66.80% |
| Net Profit Margin | 12.30% |
| Debt/Equity Ratio | 0% |
How did P2NB34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/24 02:30 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Penumbra, Inc. is covered by 30 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| null null | Baird |
| Joanne Wuensch | BMO Capital Markets Equity Research |